Clinical Trial Update: A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients [Phase 3]

View source ↗

Summary

This is an update on a Phase III trial evaluating SKB264 in EGFR-mutant non-small cell lung cancer; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SKB264

Snippet

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING